Drug Type Chemical drugs |
Synonyms |
Target |
Action inhibitors |
Mechanism HIF-1α inhibitors(Hypoxia-inducible factor 1 alpha inhibitors), HIF-2α inhibitors(Endothelial PAS domain-containing protein 1 inhibitors), ISCA2 inhibitors(iron-sulfur cluster assembly 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Clear Cell Renal Cell Carcinoma | Preclinical | United States | 09 Mar 2023 | |
Locally Advanced Clear Cell Renal Cell Carcinoma | Preclinical | United States | 09 Mar 2023 |